Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Cardiovasc Diabetol ; 18(1): 16, 2019 02 07.
Article in English | MEDLINE | ID: mdl-30732594

ABSTRACT

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i's promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob-/- mice; a rodent model of early diabetes with specific focus on coronary microvascular function. Due to leptin deficiency these mice develop metabolic syndrome/diabetes and hepatic steatosis. They also develop cardiac contractile and microvascular dysfunction and are thus a promising model for translational studies of cardiometabolic diseases. We investigated whether this mouse model responded in a human-like manner to empagliflozin treatment in terms of metabolic parameters and tested the hypothesis that it could exert direct effects on coronary microvascular function and contractile performance. METHODS: Lean, ob/ob-/- untreated and ob/ob-/- treated with SGLT2i were followed for 10 weeks. Coronary flow velocity reserve (CFVR) and fractional area change (FAC) were monitored with non-invasive Doppler ultrasound imaging. Food intake, urinary glucose excursion and glucose control via HbA1c measurements were followed throughout the study. Liver steatosis was assessed by histology and metabolic parameters determined at the end of the study. RESULTS: Sodium-glucose cotransporter 2 inhibitors treatment of ob/ob-/- animals resulted in a switch to a more catabolic state as observed in clinical studies: blood cholesterol and HbA1c were decreased whereas glucagon/insulin ratio and ketone levels were increased. SGLT2i treatment reduced liver triglyceride, steatosis and alanine aminotransferase, an indicator for liver dysfunction. L-Arginine/ADMA ratio, a marker for endothelial function was increased. SGLT2i treatment improved both cardiac contractile function and coronary microvascular function as indicated by improvement of FAC and CFVR, respectively. CONCLUSIONS: Sodium-glucose cotransporter 2 inhibitors treatment of ob/ob-/- mice mimics major clinical findings regarding metabolism and cardiovascular improvements and is thus a useful translational model. We demonstrate that SGLT2 inhibition improves coronary microvascular function and contractile performance, two measures with strong predictive values in humans for CV outcome, alongside with the known metabolic changes in a preclinical model for prediabetes and heart failure.


Subject(s)
Benzhydryl Compounds/pharmacology , Coronary Artery Disease/prevention & control , Coronary Circulation/drug effects , Diabetic Angiopathies/prevention & control , Diabetic Cardiomyopathies/prevention & control , Glucosides/pharmacology , Microcirculation/drug effects , Myocardial Contraction/drug effects , Obesity/complications , Prediabetic State/drug therapy , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Ventricular Function, Left/drug effects , Animals , Biomarkers/blood , Biomarkers/urine , Coronary Artery Disease/etiology , Coronary Artery Disease/metabolism , Coronary Artery Disease/physiopathology , Diabetic Angiopathies/etiology , Diabetic Angiopathies/metabolism , Diabetic Angiopathies/physiopathology , Diabetic Cardiomyopathies/etiology , Diabetic Cardiomyopathies/metabolism , Diabetic Cardiomyopathies/physiopathology , Disease Models, Animal , Energy Metabolism/drug effects , Male , Mice, Inbred C57BL , Obesity/metabolism , Prediabetic State/complications , Prediabetic State/metabolism , Sodium-Glucose Transporter 2/metabolism
2.
Circ Res ; 116(4): 642-52, 2015 Feb 13.
Article in English | MEDLINE | ID: mdl-25556206

ABSTRACT

RATIONALE: In human genetic studies a single nucleotide polymorphism within the salt-inducible kinase 1 (SIK1) gene was associated with hypertension. Lower SIK1 activity in vascular smooth muscle cells (VSMCs) leads to decreased sodium-potassium ATPase activity, which associates with increased vascular tone. Also, SIK1 participates in a negative feedback mechanism on the transforming growth factor-ß1 signaling and downregulation of SIK1 induces the expression of extracellular matrix remodeling genes. OBJECTIVE: To evaluate whether reduced expression/activity of SIK1 alone or in combination with elevated salt intake could modify the structure and function of the vasculature, leading to higher blood pressure. METHODS AND RESULTS: SIK1 knockout (sik1(-/-)) and wild-type (sik1(+/+)) mice were challenged to a normal- or chronic high-salt intake (1% NaCl). Under normal-salt conditions, the sik1(-/-) mice showed increased collagen deposition in the aorta but similar blood pressure compared with the sik1(+/+) mice. During high-salt intake, the sik1(+/+) mice exhibited an increase in SIK1 expression in the VSMCs layer of the aorta, whereas the sik1(-/-) mice exhibited upregulated transforming growth factor-ß1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, higher systolic blood pressure, and signs of cardiac hypertrophy. In vitro knockdown of SIK1 induced upregulation of collagen in aortic adventitial fibroblasts and enhanced the expression of contractile markers and of endothelin-1 in VSMCs. CONCLUSIONS: Vascular SIK1 activation might represent a novel mechanism involved in the prevention of high blood pressure development triggered by high-salt intake through the modulation of the contractile phenotype of VSMCs via transforming growth factor-ß1-signaling inhibition.


Subject(s)
Aorta/enzymology , Arterial Pressure , Hypertension/enzymology , Protein Serine-Threonine Kinases/deficiency , Vascular Remodeling , Adventitia/enzymology , Adventitia/pathology , Animals , Aorta/pathology , Aorta/physiopathology , Cells, Cultured , Collagen/metabolism , Endothelin-1/metabolism , Fibroblasts/enzymology , Fibroblasts/pathology , Genotype , Humans , Hypertension/etiology , Hypertension/genetics , Hypertension/pathology , Hypertension/physiopathology , Mice, Knockout , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/pathology , Muscle, Smooth, Vascular/physiopathology , Myocytes, Smooth Muscle/enzymology , Myocytes, Smooth Muscle/pathology , Natriuresis , Phenotype , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , RNA Interference , Signal Transduction , Sodium Chloride, Dietary , Sympathetic Nervous System/physiopathology , Transfection , Transforming Growth Factor beta1/metabolism , Vasoconstriction
3.
Arterioscler Thromb Vasc Biol ; 33(12): 2707-14, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24115030

ABSTRACT

OBJECTIVE: High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. APPROACH AND RESULTS: sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. CONCLUSIONS: These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.


Subject(s)
Aorta/enzymology , Aortic Diseases/enzymology , Atherosclerosis/enzymology , Cholesterol Ester Transfer Proteins/metabolism , Group II Phospholipases A2/metabolism , Acetates/pharmacology , Animals , Aorta/drug effects , Aorta/pathology , Aortic Diseases/blood , Aortic Diseases/drug therapy , Aortic Diseases/genetics , Aortic Diseases/pathology , Apolipoprotein E3/genetics , Apolipoprotein E3/metabolism , Apolipoproteins B/genetics , Apolipoproteins B/metabolism , Atherosclerosis/blood , Atherosclerosis/drug therapy , Atherosclerosis/genetics , Atherosclerosis/pathology , Cholesterol Ester Transfer Proteins/blood , Cholesterol Ester Transfer Proteins/genetics , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Female , Group II Phospholipases A2/antagonists & inhibitors , Group II Phospholipases A2/blood , Group II Phospholipases A2/genetics , Humans , Hypercholesterolemia/complications , Hypercholesterolemia/enzymology , Hypercholesterolemia/genetics , Indoles/pharmacology , Keto Acids , Lipoproteins, VLDL/blood , Liver/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Plaque, Atherosclerotic
4.
Front Cardiovasc Med ; 8: 753470, 2021.
Article in English | MEDLINE | ID: mdl-34722683

ABSTRACT

Objective: After myocardial infarction (MI), the non-infarcted left ventricle (LV) ensures appropriate contractile function of the heart. Metabolic disturbance in this region greatly exacerbates post-MI heart failure (HF) pathology. This study aimed to provide a comprehensive understanding of the metabolic derangements occurring in the non-infarcted LV that could trigger cardiovascular deterioration. Methods and Results: We used a pig model that progressed into chronic HF over 3 months following MI induction. Integrated gene and metabolite signatures revealed region-specific perturbations in amino acid- and lipid metabolism, insulin signaling and, oxidative stress response. Remote LV, in particular, showed impaired glutamine and arginine metabolism, altered synthesis of lipids, glucose metabolism disorder, and increased insulin resistance. LPIN1, PPP1R3C, PTPN1, CREM, and NR0B2 were identified as the main effectors in metabolism dysregulation in the remote zone and were found differentially expressed also in the myocardium of patients with ischemic and/or dilated cardiomyopathy. In addition, a simultaneous significant decrease in arginine levels and altered PRCP, PTPN1, and ARF6 expression suggest alterations in vascular function in remote area. Conclusions: This study unravels an array of dysregulated genes and metabolites putatively involved in maladaptive metabolic and vascular remodeling in the non-infarcted myocardium and may contribute to the development of more precise therapies to mitigate progression of chronic HF post-MI.

5.
J Diabetes Res ; 2019: 9727952, 2019.
Article in English | MEDLINE | ID: mdl-30949516

ABSTRACT

BACKGROUND: There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE∗3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/- (GK+/-) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice respond similarly to lipid-lowering and antidiabetic drugs as humans. The objective of this study was to evaluate/characterize the APOE∗3-Leiden.glucokinase+/- (E3L.GK+/-) mouse as a novel disease model to study the metabolic syndrome and diabetic complications. METHODS: Female E3L.GK+/-, E3L, and GK+/- mice were fed fat- and cholesterol-containing diets for 37 weeks, and plasma parameters were measured throughout. Development of diabetic macro- and microvascular complications was evaluated. RESULTS: Cholesterol and triglyceride levels were significantly elevated in E3L and E3L.GK+/- mice compared to GK+/- mice, whereas fasting glucose was significantly increased in E3L.GK+/- and GK+/- mice compared to E3L. Atherosclerotic lesion size was increased 2.2-fold in E3L.GK+/- mice as compared to E3L (p = 0.037), which was predicted by glucose exposure (R 2 = 0.636, p = 0.001). E3L and E3L.GK+/- mice developed NASH with severe inflammation and fibrosis which, however, was not altered by introduction of the defective GK phenotype, whereas mild kidney pathology with tubular vacuolization was present in all three phenotypes. CONCLUSIONS: We conclude that the E3L.GK+/- mouse is a promising novel diet-inducible disease model for investigation of the etiology and evaluation of drug treatment on diabetic atherosclerosis.


Subject(s)
Apolipoprotein E3/genetics , Atherosclerosis/genetics , Diabetes Complications/genetics , Diabetes Mellitus, Type 2/genetics , Disease Models, Animal , Dyslipidemias/genetics , Animals , Atherosclerosis/blood , Blood Glucose/metabolism , Cholesterol/blood , Diabetes Complications/blood , Diabetes Mellitus, Type 2/blood , Dyslipidemias/blood , Female , Heterozygote , Inflammation , Lipids/blood , Mice , Mice, Knockout , Phenotype , Risk , Translational Research, Biomedical , Triglycerides/metabolism
6.
Sci Transl Med ; 10(456)2018 08 29.
Article in English | MEDLINE | ID: mdl-30158152

ABSTRACT

Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly associated with poor clinical outcomes. Current management of hyperphosphatemia with dietary restriction and oral phosphate binders often proves inadequate. Tenapanor, a minimally absorbed, small-molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), acts locally in the gastrointestinal tract to inhibit sodium absorption. Because tenapanor also reduces intestinal phosphate absorption, it may have potential as a therapy for hyperphosphatemia. We investigated the mechanism by which tenapanor reduces gastrointestinal phosphate uptake, using in vivo studies in rodents and translational experiments on human small intestinal stem cell-derived enteroid monolayers to model ion transport physiology. We found that tenapanor produces its effect by modulating tight junctions, which increases transepithelial electrical resistance (TEER) and reduces permeability to phosphate, reducing paracellular phosphate absorption. NHE3-deficient monolayers mimicked the phosphate phenotype of tenapanor treatment, and tenapanor did not affect TEER or phosphate flux in the absence of NHE3. Tenapanor also prevents active transcellular phosphate absorption compensation by decreasing the expression of NaPi2b, the major active intestinal phosphate transporter. In healthy human volunteers, tenapanor (15 mg, given twice daily for 4 days) increased stool phosphorus and decreased urinary phosphorus excretion. We determined that tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux, an effect mediated exclusively via on-target NHE3 inhibition.


Subject(s)
Cell Membrane Permeability/drug effects , Gastrointestinal Tract/metabolism , Isoquinolines/pharmacology , Phosphates/metabolism , Sodium-Hydrogen Exchanger 3/antagonists & inhibitors , Sulfonamides/pharmacology , Adult , Aged , Animals , Base Sequence , Cells, Cultured , Electric Impedance , Epithelium/metabolism , Female , Healthy Volunteers , Humans , Hydrogen-Ion Concentration , Intestinal Absorption/drug effects , Ions/urine , Male , Mice , Middle Aged , Potassium/metabolism , Protons , Rats , Sodium/metabolism , Sodium-Hydrogen Exchanger 3/metabolism , Tight Junction Proteins/metabolism , Young Adult
7.
Cardiovasc Res ; 71(3): 586-95, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16759648

ABSTRACT

OBJECTIVE: Matrix metalloproteinases (MMPs) form a large family of enzymes that collectively can degrade all components of the extracellular matrix, and there is widespread interest in developing MMP inhibitors for the prevention of atherosclerotic plaque rupture. We have therefore investigated the effects of a broad-spectrum MMP inhibitor, RS-130830, on plaque development and stability. This compound inhibits a wide range of MMPs at concentrations below 20 nmol/L. METHODS: Apolipoprotein E knockout mice were fed a Western diet. Dietary administration of RS-130830 commenced at the same time as fat-feeding and continued for 8, 12, 26 or 36 weeks. To investigate the effect of RS-130830 on established plaques, mice were fed high-fat diet for 16 weeks before initiation of drug treatment and were terminated 20 weeks after this. RESULTS: Broad-spectrum MMP inhibition was associated with a significant increase in plaque area, but there was no change in the incidence of plaque rupture. There were unfavourable changes in phenotypic characteristics associated with plaque instability, such as an increased lipid content and decreased collagen content. CONCLUSIONS: These data suggest that broad-spectrum MMP inhibition RS-130830 does not have a beneficial effect on atherosclerosis in the apolipoprotein E knockout mouse model, and indicate that more selective compounds would be preferable.


Subject(s)
Atherosclerosis/drug therapy , Enzyme Inhibitors/therapeutic use , Hydroxamic Acids/therapeutic use , Matrix Metalloproteinase Inhibitors , Animals , Apolipoproteins E/genetics , Atherosclerosis/metabolism , Atherosclerosis/pathology , Brachiocephalic Trunk/metabolism , Brachiocephalic Trunk/pathology , Collagen/metabolism , Diet, Atherogenic , Disease Models, Animal , Drug Evaluation, Preclinical , Enzyme Inhibitors/toxicity , Female , Hydroxamic Acids/toxicity , Lipid Metabolism/drug effects , Lipids/blood , Male , Mice , Mice, Knockout , Rupture, Spontaneous/prevention & control , Survival Analysis
8.
Arterioscler Thromb Vasc Biol ; 25(1): 180-5, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15539621

ABSTRACT

OBJECTIVE: We investigated the potential role of ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motif type I) in atherogenesis. METHODS AND RESULTS: ADAMTS-1 is expressed at the highest levels in the aorta when compared with other human tissues examined. Immunolocalization studies in human aorta and coronary artery indicate that ADAMTS-1 expression is mainly seen at low levels in the medial layer, but upregulated in the intima when plaque is present. We found that ADAMTS-1 mRNA levels are significantly higher in proliferating/migrating cultured primary aortic vascular smooth muscle cells (VSMCs) compared with resting/confluent cells. Using the mouse carotid artery flow cessation model, we show that there are differences in vessel remodeling in ADAMTS-1 transgenic/apoE-deficient mice compared with apoE deficiency alone, particularly a significant increase in intimal hyperplasia. We show that ADAMTS-1 can cleave the large versican containing proteoglycan population purified from cultured human aortic VSMCs. Finally, using versican peptide substrates, we show data suggesting that ADAMTS-1 cleaves versican at multiple sites. CONCLUSIONS: We hypothesize that ADAMTS-1 may promote atherogenesis by cleaving extracellular matrix proteins such as versican and promoting VSMC migration.


Subject(s)
Arteriosclerosis/pathology , Carotid Artery, Common/pathology , Chondroitin Sulfate Proteoglycans/metabolism , Disintegrins/physiology , Immunohistochemistry/methods , Metalloendopeptidases/physiology , Peptide Hydrolases/metabolism , ADAM Proteins , ADAMTS1 Protein , Adolescent , Animals , Arteriosclerosis/metabolism , Carotid Artery, Common/chemistry , Carotid Artery, Common/metabolism , Carotid Artery, Common/surgery , Cell Line , Disease Models, Animal , Disintegrins/biosynthesis , Disintegrins/immunology , Disintegrins/metabolism , Humans , Hydrolysis , Lectins, C-Type , Ligation/methods , Male , Metalloendopeptidases/biosynthesis , Metalloendopeptidases/immunology , Metalloendopeptidases/metabolism , Mice , Mice, Inbred C57BL , Middle Aged , Muscle, Smooth, Vascular/chemistry , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/chemistry , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Neovascularization, Pathologic/pathology , Reverse Transcriptase Polymerase Chain Reaction/methods , Versicans
9.
J Diabetes Res ; 2016: 8630961, 2016.
Article in English | MEDLINE | ID: mdl-27774459

ABSTRACT

Aim. Models combining diabetes and atherosclerosis are important in evaluating the cardiovascular (CV) effects and safety of antidiabetes drugs in the development of treatments targeting CV complications. Our aim was to evaluate if crossing the heterozygous glucokinase knockout mouse (GK+/-) and hyperlipidemic mouse deficient in apolipoprotein E (ApoE-/-) will generate a disease model exhibiting a diabetic and macrovascular phenotype. Methods. The effects of defective glucokinase on the glucose metabolism and on the progression and regression of atherosclerosis on high-fat diets were studied in both genders of GK+/-ApoE-/- and ApoE-/- mice. Coronary vascular function of the female GK+/-ApoE-/- and ApoE-/- mice was also investigated. Results. GK+/-ApoE-/- mice show a stable hyperglycemia which was increased on Western diet. In oral glucose tolerance test, GK+/-ApoE-/- mice showed significant glucose intolerance and impaired glucose-stimulated insulin secretion. Plasma lipids were comparable with ApoE-/- mice; nevertheless the GK+/-ApoE-/- mice showed slightly increased atherosclerosis development. Conclusions. The GK+/-ApoE-/- mice showed a stable and reproducible hyperglycemia, accelerated atherosclerotic lesion progression, and no lesion regression after lipid lowering. This novel model provides a promising tool for drug discovery, enabling the evaluation of compound effects against both diabetic and cardiovascular endpoints simultaneously in one animal model.


Subject(s)
Apolipoproteins E/metabolism , Atherosclerosis/metabolism , Glucokinase/metabolism , Hyperglycemia/metabolism , Animals , Aorta/metabolism , Aorta/pathology , Apolipoproteins E/genetics , Atherosclerosis/genetics , Atherosclerosis/pathology , Diet, High-Fat , Disease Progression , Female , Glucokinase/genetics , Hyperglycemia/genetics , Hyperglycemia/pathology , Lipids/blood , Male , Mice , Mice, Knockout , Myocardium/metabolism , Myocardium/pathology
10.
Am J Pathol ; 160(2): 433-40, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11839563

ABSTRACT

Carcinoma ex pleomorphic adenoma (CexPA) is a carcinoma developing within a pre-existing benign pleomorphic adenoma (PA). Here we describe the identification and characterization of a series of genetic events leading to translocation, deletion/amplification, and overexpression of the HMGIC and MDM2 genes in a CexPA at an early stage of development. The tumor had a pseudodiploid stemline karyotype with a del(5)(q22-23q32-33) and a t(10;12)(p15;q14-15). In addition, there were several sidelines with double minute chromosomes (dmin) or homogeneously staining regions (hsr). Fluorescence in situ hybridization (FISH) mapping revealed that the 12q14-15 breakpoint was located centromeric to HMGIC and that the entire gene was juxtaposed to the der(10) chromosome. Detailed analysis of cells with dmin and hsr revealed that HMGIC and MDM2 were deleted from the der(10) and that the dmin and hsr were strongly positive for both genes. Southern blot analysis confirmed that both HMGIC and MDM2 were amplified and that no gross rearrangements of the genes had occurred. Immunostaining revealed that the HMGIC protein was highly overexpressed particularly in the large polymorphic cells within the carcinomatous part of the tumor. These findings suggest that amplification and overexpression of HMGIC and possibly MDM2 might be important genetic events that may contribute to malignant transformation of benign PA.


Subject(s)
Adenocarcinoma/genetics , Adenoma, Pleomorphic/genetics , HMGA2 Protein/genetics , Nuclear Proteins , Parotid Neoplasms/genetics , Proto-Oncogene Proteins/genetics , Adenocarcinoma/pathology , Adenocarcinoma/physiopathology , Adenoma, Pleomorphic/pathology , Adenoma, Pleomorphic/physiopathology , Adult , Cell Transformation, Neoplastic , Female , Gene Amplification , Gene Deletion , Gene Expression Regulation, Neoplastic , HMGA2 Protein/metabolism , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Karyotyping , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Parotid Neoplasms/pathology , Parotid Neoplasms/physiopathology , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-mdm2 , Translocation, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL